SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice.

Diabetes Ther · 2019 · PMC6778582 · PMID 31290126

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

This stipulation followed the suggestion that rosiglitazone was associated with a significant increase in the risk of MI and a borderline significant increase in CV death [ 72 ].

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.